Trial readiness in cavernous angiomas with symptomatic hemorrhage (cash)

Sean P. Polster, Ying Cao, Timothy Carroll, Kelly Flemming, Romuald Girard, Daniel Hanley, Nicholas Hobson, Helen Kim, James Koenig, Janne Koskimäki, Karen Lane, Jennifer J. Majersik, Nichol Mcbee, Leslie Morrison, Robert Ph D. Shenkar, Agnieszka Stadnik, Richard E. Thompson, Joseph Zabramski, Hussein A. Zeineddine, Issam A. Awad

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

BACKGROUND Brain cavernous angiomas with symptomatic hemorrhage (CASH) are uncommon but exact a heavy burden of neurological disability from recurrent bleeding, for which there is no proven therapy. Candidate drugs to stabilize the CASH lesion and prevent rebleeding will ultimately require testing of safety and efficacy in multisite clinical trials. Much progress has been made in understanding the epidemiology of CASH, and novel biomarkers have been linked to the biological mechanisms and clinical activity in lesions. Yet, the ability to enroll and risk-stratify CASH subjects has never been assessed prospectively at multiple sites. Biomarkers and other outcomes have not been evaluated for their sensitivity and reliability, nor have they been harmonized across sites. OBJECTIVE To address knowledge gaps and establish a research network as infrastructure for future clinical trials, through the Trial Readiness grant mechanism, funded by National Institute of Neurological Disorders and Stroke/National Institutes of Health. METHODS This project includes an observational cohort study to assess (1) the feasibility of screening, enrollment rates, baseline disease categorization, and follow-up of CASH using common data elements at multiple sites, (2) the reliability of imaging biomarkers including quantitative susceptibility mapping and permeability measures that have been shown to correlate with lesion activity, and (3) the rates of recurrent hemorrhage and change in functional status and biomarker measurements during prospective follow-up. EXPECTED OUTCOMES We propose a harmonized multisite assessment of enrollment rates of CASH, baseline features relevant to stratification in clinical trials, and follow-up assessments of functional outcomes in relation to clinical bleeds. We introduce novel biomarkers of vascular leak and hemorrhage, with firm mechanistic foundations, which have been linked to clinical disease activity. We shall test their reliability and validity at multiple sites, and assess their changes over time, with and without clinical rebleeds, hence their fitness as outcome instruments in clinical trials. DISCUSSION The timing cannot be more opportune, with therapeutic targets identified, exceptional collaboration among researchers and the patient community, along with several drugs ready to benefit from development of a path to clinical testing using this network in the next 5 years. ©

Original languageEnglish (US)
Pages (from-to)954-964
Number of pages11
JournalClinical neurosurgery
Volume84
Issue number4
DOIs
StatePublished - Apr 1 2019

Fingerprint

Cavernous Hemangioma
Hemorrhage
Biomarkers
Clinical Trials
National Institute of Neurological Disorders and Stroke
Critical Pathways
Organized Financing
National Institutes of Health (U.S.)
Reproducibility of Results
Pharmaceutical Preparations
Observational Studies
Blood Vessels
Permeability
Epidemiology
Cohort Studies
Research Personnel
Outcome Assessment (Health Care)
Safety

Keywords

  • Biomarkers
  • Cavernous angioma
  • Cerebral cavernous malformation (CCM)
  • Drug development
  • Symptomatic hemorrhage
  • Trial readiness

ASJC Scopus subject areas

  • Surgery
  • Clinical Neurology

Cite this

Polster, S. P., Cao, Y., Carroll, T., Flemming, K., Girard, R., Hanley, D., ... Awad, I. A. (2019). Trial readiness in cavernous angiomas with symptomatic hemorrhage (cash). Clinical neurosurgery, 84(4), 954-964. https://doi.org/10.1093/neuros/nyy108

Trial readiness in cavernous angiomas with symptomatic hemorrhage (cash). / Polster, Sean P.; Cao, Ying; Carroll, Timothy; Flemming, Kelly; Girard, Romuald; Hanley, Daniel; Hobson, Nicholas; Kim, Helen; Koenig, James; Koskimäki, Janne; Lane, Karen; Majersik, Jennifer J.; Mcbee, Nichol; Morrison, Leslie; Shenkar, Robert Ph D.; Stadnik, Agnieszka; Thompson, Richard E.; Zabramski, Joseph; Zeineddine, Hussein A.; Awad, Issam A.

In: Clinical neurosurgery, Vol. 84, No. 4, 01.04.2019, p. 954-964.

Research output: Contribution to journalArticle

Polster, SP, Cao, Y, Carroll, T, Flemming, K, Girard, R, Hanley, D, Hobson, N, Kim, H, Koenig, J, Koskimäki, J, Lane, K, Majersik, JJ, Mcbee, N, Morrison, L, Shenkar, RPD, Stadnik, A, Thompson, RE, Zabramski, J, Zeineddine, HA & Awad, IA 2019, 'Trial readiness in cavernous angiomas with symptomatic hemorrhage (cash)', Clinical neurosurgery, vol. 84, no. 4, pp. 954-964. https://doi.org/10.1093/neuros/nyy108
Polster, Sean P. ; Cao, Ying ; Carroll, Timothy ; Flemming, Kelly ; Girard, Romuald ; Hanley, Daniel ; Hobson, Nicholas ; Kim, Helen ; Koenig, James ; Koskimäki, Janne ; Lane, Karen ; Majersik, Jennifer J. ; Mcbee, Nichol ; Morrison, Leslie ; Shenkar, Robert Ph D. ; Stadnik, Agnieszka ; Thompson, Richard E. ; Zabramski, Joseph ; Zeineddine, Hussein A. ; Awad, Issam A. / Trial readiness in cavernous angiomas with symptomatic hemorrhage (cash). In: Clinical neurosurgery. 2019 ; Vol. 84, No. 4. pp. 954-964.
@article{2823ceff7a7f4393b0313b7f568784d5,
title = "Trial readiness in cavernous angiomas with symptomatic hemorrhage (cash)",
abstract = "BACKGROUND Brain cavernous angiomas with symptomatic hemorrhage (CASH) are uncommon but exact a heavy burden of neurological disability from recurrent bleeding, for which there is no proven therapy. Candidate drugs to stabilize the CASH lesion and prevent rebleeding will ultimately require testing of safety and efficacy in multisite clinical trials. Much progress has been made in understanding the epidemiology of CASH, and novel biomarkers have been linked to the biological mechanisms and clinical activity in lesions. Yet, the ability to enroll and risk-stratify CASH subjects has never been assessed prospectively at multiple sites. Biomarkers and other outcomes have not been evaluated for their sensitivity and reliability, nor have they been harmonized across sites. OBJECTIVE To address knowledge gaps and establish a research network as infrastructure for future clinical trials, through the Trial Readiness grant mechanism, funded by National Institute of Neurological Disorders and Stroke/National Institutes of Health. METHODS This project includes an observational cohort study to assess (1) the feasibility of screening, enrollment rates, baseline disease categorization, and follow-up of CASH using common data elements at multiple sites, (2) the reliability of imaging biomarkers including quantitative susceptibility mapping and permeability measures that have been shown to correlate with lesion activity, and (3) the rates of recurrent hemorrhage and change in functional status and biomarker measurements during prospective follow-up. EXPECTED OUTCOMES We propose a harmonized multisite assessment of enrollment rates of CASH, baseline features relevant to stratification in clinical trials, and follow-up assessments of functional outcomes in relation to clinical bleeds. We introduce novel biomarkers of vascular leak and hemorrhage, with firm mechanistic foundations, which have been linked to clinical disease activity. We shall test their reliability and validity at multiple sites, and assess their changes over time, with and without clinical rebleeds, hence their fitness as outcome instruments in clinical trials. DISCUSSION The timing cannot be more opportune, with therapeutic targets identified, exceptional collaboration among researchers and the patient community, along with several drugs ready to benefit from development of a path to clinical testing using this network in the next 5 years. {\circledC}",
keywords = "Biomarkers, Cavernous angioma, Cerebral cavernous malformation (CCM), Drug development, Symptomatic hemorrhage, Trial readiness",
author = "Polster, {Sean P.} and Ying Cao and Timothy Carroll and Kelly Flemming and Romuald Girard and Daniel Hanley and Nicholas Hobson and Helen Kim and James Koenig and Janne Koskim{\"a}ki and Karen Lane and Majersik, {Jennifer J.} and Nichol Mcbee and Leslie Morrison and Shenkar, {Robert Ph D.} and Agnieszka Stadnik and Thompson, {Richard E.} and Joseph Zabramski and Zeineddine, {Hussein A.} and Awad, {Issam A.}",
year = "2019",
month = "4",
day = "1",
doi = "10.1093/neuros/nyy108",
language = "English (US)",
volume = "84",
pages = "954--964",
journal = "Neurosurgery",
issn = "0148-396X",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Trial readiness in cavernous angiomas with symptomatic hemorrhage (cash)

AU - Polster, Sean P.

AU - Cao, Ying

AU - Carroll, Timothy

AU - Flemming, Kelly

AU - Girard, Romuald

AU - Hanley, Daniel

AU - Hobson, Nicholas

AU - Kim, Helen

AU - Koenig, James

AU - Koskimäki, Janne

AU - Lane, Karen

AU - Majersik, Jennifer J.

AU - Mcbee, Nichol

AU - Morrison, Leslie

AU - Shenkar, Robert Ph D.

AU - Stadnik, Agnieszka

AU - Thompson, Richard E.

AU - Zabramski, Joseph

AU - Zeineddine, Hussein A.

AU - Awad, Issam A.

PY - 2019/4/1

Y1 - 2019/4/1

N2 - BACKGROUND Brain cavernous angiomas with symptomatic hemorrhage (CASH) are uncommon but exact a heavy burden of neurological disability from recurrent bleeding, for which there is no proven therapy. Candidate drugs to stabilize the CASH lesion and prevent rebleeding will ultimately require testing of safety and efficacy in multisite clinical trials. Much progress has been made in understanding the epidemiology of CASH, and novel biomarkers have been linked to the biological mechanisms and clinical activity in lesions. Yet, the ability to enroll and risk-stratify CASH subjects has never been assessed prospectively at multiple sites. Biomarkers and other outcomes have not been evaluated for their sensitivity and reliability, nor have they been harmonized across sites. OBJECTIVE To address knowledge gaps and establish a research network as infrastructure for future clinical trials, through the Trial Readiness grant mechanism, funded by National Institute of Neurological Disorders and Stroke/National Institutes of Health. METHODS This project includes an observational cohort study to assess (1) the feasibility of screening, enrollment rates, baseline disease categorization, and follow-up of CASH using common data elements at multiple sites, (2) the reliability of imaging biomarkers including quantitative susceptibility mapping and permeability measures that have been shown to correlate with lesion activity, and (3) the rates of recurrent hemorrhage and change in functional status and biomarker measurements during prospective follow-up. EXPECTED OUTCOMES We propose a harmonized multisite assessment of enrollment rates of CASH, baseline features relevant to stratification in clinical trials, and follow-up assessments of functional outcomes in relation to clinical bleeds. We introduce novel biomarkers of vascular leak and hemorrhage, with firm mechanistic foundations, which have been linked to clinical disease activity. We shall test their reliability and validity at multiple sites, and assess their changes over time, with and without clinical rebleeds, hence their fitness as outcome instruments in clinical trials. DISCUSSION The timing cannot be more opportune, with therapeutic targets identified, exceptional collaboration among researchers and the patient community, along with several drugs ready to benefit from development of a path to clinical testing using this network in the next 5 years. ©

AB - BACKGROUND Brain cavernous angiomas with symptomatic hemorrhage (CASH) are uncommon but exact a heavy burden of neurological disability from recurrent bleeding, for which there is no proven therapy. Candidate drugs to stabilize the CASH lesion and prevent rebleeding will ultimately require testing of safety and efficacy in multisite clinical trials. Much progress has been made in understanding the epidemiology of CASH, and novel biomarkers have been linked to the biological mechanisms and clinical activity in lesions. Yet, the ability to enroll and risk-stratify CASH subjects has never been assessed prospectively at multiple sites. Biomarkers and other outcomes have not been evaluated for their sensitivity and reliability, nor have they been harmonized across sites. OBJECTIVE To address knowledge gaps and establish a research network as infrastructure for future clinical trials, through the Trial Readiness grant mechanism, funded by National Institute of Neurological Disorders and Stroke/National Institutes of Health. METHODS This project includes an observational cohort study to assess (1) the feasibility of screening, enrollment rates, baseline disease categorization, and follow-up of CASH using common data elements at multiple sites, (2) the reliability of imaging biomarkers including quantitative susceptibility mapping and permeability measures that have been shown to correlate with lesion activity, and (3) the rates of recurrent hemorrhage and change in functional status and biomarker measurements during prospective follow-up. EXPECTED OUTCOMES We propose a harmonized multisite assessment of enrollment rates of CASH, baseline features relevant to stratification in clinical trials, and follow-up assessments of functional outcomes in relation to clinical bleeds. We introduce novel biomarkers of vascular leak and hemorrhage, with firm mechanistic foundations, which have been linked to clinical disease activity. We shall test their reliability and validity at multiple sites, and assess their changes over time, with and without clinical rebleeds, hence their fitness as outcome instruments in clinical trials. DISCUSSION The timing cannot be more opportune, with therapeutic targets identified, exceptional collaboration among researchers and the patient community, along with several drugs ready to benefit from development of a path to clinical testing using this network in the next 5 years. ©

KW - Biomarkers

KW - Cavernous angioma

KW - Cerebral cavernous malformation (CCM)

KW - Drug development

KW - Symptomatic hemorrhage

KW - Trial readiness

UR - http://www.scopus.com/inward/record.url?scp=85062981880&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85062981880&partnerID=8YFLogxK

U2 - 10.1093/neuros/nyy108

DO - 10.1093/neuros/nyy108

M3 - Article

C2 - 29660039

AN - SCOPUS:85062981880

VL - 84

SP - 954

EP - 964

JO - Neurosurgery

JF - Neurosurgery

SN - 0148-396X

IS - 4

ER -